**Glossary of some Pharmacogenetic Terms**


#### **Useful Internet Resources and databases:**

**Figure 1.** Example of diversity in prevalence of clinically relevant polymorphisms. (\*Western Sydney Population com‐

bined data. WSLHD population is a mix of Caucasians, Asians and Africans.)

90 Drug Discovery


**•** Databases: ensembl (www.ensembl.org/index.html) and HapMap (www.hapmap.org/cgiperl/gbrowse/hapmap\_B35)

[9] Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment,

Drug Interactions, Pharmacogenomics and Cardiovascular Complication

http://dx.doi.org/10.5772/48423

93

[10] AHA (2008) Heart Disease and Stroke Statistics - 2008 Update. American Heart Asso‐

[11] Brodde OE (2008) Beta-1 and beta-2 adrenoceptor polymorphisms: functional impor‐ tance, impact on cardiovascular diseases and drug responses. Pharmacol Ther

[12] Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular re‐

[13] Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA (2005) Beta2-adre‐ nergic receptor genotype and survival among patients receiving beta-blocker therapy

[14] Lanfear DE, Spertus JA, McLeod HL (2006) Beta2-adrenergic receptor genotype pre‐ dicts survival: implications and future directions. J Cardiovasc Nurs 21:474-477

[15] Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA (2008) beta-adrenergic receptor gene polymorphisms and be‐ ta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 84:715-721

[16] Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, Hin‐ dorff LA, Lange LA, Lumley TS, Rice KM, Wiggins KL, Psaty BM (2008) beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial in‐

[17] Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, Weinmann SA, Anderson GD, Lin D (2002) Inhaled beta-2 adrenergic receptor ago‐

[18] Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC, Jr. (2001) ACC/AHA guidelines for the evaluation and man‐ agement of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Manage‐

[19] Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European popula‐ tion: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

and control of hypertension, 1988-2008. Jama 303:2043-2050

sponse to metoprolol. Clin Pharmacol Ther 74:372-379

after an acute coronary syndrome. Jama 294:1526-1533

farction and stroke. Am J Hypertens 21:290-296

nists and primary cardiac arrest. Am J Med 113:711-716

ment of Heart Failure). J Am Coll Cardiol 38:2101-2113

Pharmacogenetics 7:193-202

cation

117:1-29

